{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2019"],"data_sharing_plan":["IPD Sharing (as of January 2023): No"],"condition":["Microbial Colonization","Colorectal Cancer","Colorectal Neoplasms","Infections","Communicable Diseases"],"disease":["Microbial Colonization","Colorectal Cancer","Colorectal Neoplasms","Infections","Communicable Diseases"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2311055"],"location":["China"],"study_start_month":["7"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Chemotherapy w/wo WeiLeShu in Metastatic Colorectal Cancer","description":"A total of 50 patients with metastatic colorectal cancer will be enrolled in the study. The patients were randomly divided into the WLS-intervention group and the control group. The two groups of patients were given the most appropriate medication according to the specific conditions of the disease. Patients in the intervention group received additional oral administration of Weileshu, a probiotics product (Tongchuang Biotechnology).","dates":{"creation":"2019-07-15"},"accession":"2311055","cross_references":{"ClinicalTrials___gov":["NCT04021589"]}}